While the United States is still awaiting the launch of the first FDA-approved biosimilar epoetin alfa, erythropoiesis-stimulating agents were among the first biosimilars to become available in Europe. This month, Italian researchers published a post-authorization observational study that compared the efficacy and safety of 2 European biosimilars and the reference epoetin alfa in patients undergoing dialysis at 26 hospitals in 4 regions in Italy, and they concluded that their results support the comparable safety profiles of the originator and biosimilar products.
While the United States is still awaiting the launch of the first FDA-approved biosimilar epoetin alfa, erythropoiesis-stimulating agents were among the first biosimilars to become available in Europe. This month, Italian researchers published a post-authorization observational study that compared the efficacy and safety of European biosimilars and the reference epoetin alfa in patients undergoing dialysis at 26 hospitals in 4 regions in Italy, and they concluded that their results support the comparable safety profiles of the originator and biosimilar products.
The study, conducted between 2013 and 2015, included all adult patients with chronic kidney disease who had hemodialysis at least twice weekly and who were treated with the innovator epoetin (Eprex) or a biosimilar (Binocrit or Retacrit). Each patient was followed for 12 months after the first visit.
Click to learn more about biosimilar epoetin alfa.
The study’s outcomes comprised 3 major categories: problems related to the dialysis device (such as infections of the vascular access), cardiovascular or cerebrovascular events (such as arrhythmia that was not present at baseline), and infections (such as pneumonia).
A total of 423 patients used the originator and 444 used one of the biosimilars (440 of the biosimilar users received Binocrit). Patients who took a biosimilar were older than those who took the reference, and were more frequently affected by arrhythmia and diabetes at baseline. Those who used the originator more frequently had arteriovenous fistula and previous renal transplant, and were more frequently on transplant wait lists and had received dialysis for a longer time. There were 765 established epoetin users and 102 new patients.
A total of 274 patients (31.6%) experienced at least 1 of the safety outcomes; 123 events (29.1%) occurred in patients using the reference product and 151 (34.0%) occurred among the biosimilar users. The most common events were infections (11.5%), followed by cardiovascular and cerebrovascular conditions (10.6%), followed by problems related to the dialysis device (9.8%). A total of 127 deaths occurred in the study population (14.6%) during the 12-month follow-up period.
After adjusting for confounding factors (such as age, vascular access, heart failure, and other conditions), hazard ratio estimates were 1.0 (95% CI, 0.7-1.3) for any of the study outcomes, 0.9 (95% CI, 0.6—1.5) for infections, 0.9 (95% CI, 0.6-1.5) for cardiovascular and cerebrovascular conditions, and 1.1 (95% CI, 0.7-1.8) for device-related problems.
Results were similar to the overall population when new patients were considered as a subgroup; 33 patients (32.4%) experienced at least 1 safety outcome, and there was no statistically significant difference between biosimilar or reference users.
“The results from this study confirm the similarity in terms of safety between originator [epoetin alfa] and biosimilars when used in patients with [chronic kidney disease] receiving dialysis,” concluded the authors. “Specifically, no difference emerged between the [2] cohorts of users with regard to any kind of adverse events.”
Reference
Stoppa G, D’Amore C, Conforti A, et al. Comparative safety of originator and biosimilar epoetin alfa drugs: an observational prospective multicenter study. BioDrugs. 2018;32: 367. doi: 10.1007/s40259-018-029.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.